{"id":412093,"date":"2021-01-11T09:03:20","date_gmt":"2021-01-11T14:03:20","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=412093"},"modified":"2021-01-11T09:03:20","modified_gmt":"2021-01-11T14:03:20","slug":"matthew-moore-joins-arcutis-as-chief-business-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/matthew-moore-joins-arcutis-as-chief-business-officer\/","title":{"rendered":"Matthew Moore Joins Arcutis as Chief Business Officer"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">WESTLAKE VILLAGE, Calif., Jan.  11, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=d71R2jIu5rWGTOdj9dOw95q9M0xuqpJkuPzW_9-EhE-IaX6Hn44RqJiA1Cz4_9b9OST-wn8RnS-rFgcNv57ej_bf1DH1P2aHHi4-XRo0of4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Arcutis Biotherapeutics, Inc<\/a>. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Matthew Moore has joined the company as Chief Business Officer. Mr. Moore brings to Arcutis over 20 years of strategy, transaction and operations experience in the biopharmaceutical industry. Most recently, he served as Vice President, Corporate Business Development and Alliance Management at Allergan, where he led worldwide strategy and business development for the company\u2019s $4B+ Medical Aesthetics business unit.<\/p>\n<p align=\"justify\">\u201cWe are thrilled to add Matt to our executive team. Like the rest of our senior team, Matt brings a deep understanding of dermatology markets, and he adds important expertise in corporate strategy, business development, and alliance management. His extensive experience creating shareholder value through successful business development will be a key enabler as we continue to build Arcutis into one of the industry\u2019s leading dermatology companies,\u201d said <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wr7_FF1bxTJunv8U61twlmsT3X5diimr2-SIKSVIovLDDqZuwyZ4LzZVpBRuTpr90hLHAbVYYLN7Wd68tLSe7rhGy2gf5O7fRCtpNbIjtNXsNiCqnzJ2MsakNb1Dpf2S\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Frank Watanabe<\/a>, Arcutis\u2019 President and Chief Executive Officer. \u201cWe at Arcutis are focused on elevating the standard of care for dermatological diseases, and his strategic insights and deal execution will play an important role in helping us to realize that goal.\u201d<\/p>\n<p align=\"justify\">\u201cI am delighted to join Arcutis at such an exciting time for the company,\u201d said Mr. Moore. \u201cArcutis has established itself as a leader in medical dermatology and is uniquely positioned to fill the innovation gap in this therapeutic area. I have been impressed by the pace of progress achieved to date, and look forward to working with the team to help make Arcutis the preeminent, innovation-driven medical dermatology company.\u201d<\/p>\n<p align=\"justify\">During his tenure at Allergan and its predecessor companies, Actavis and Forest Labs, Mr. Moore was responsible for creating and executing business development growth strategies across multiple therapeutic areas including medical aesthetics, neuroscience, anti-infectives and hospital products. In addition, Mr. Moore served as a key deal team member in Actavis\u2019 transformational acquisition of Allergan and Allergan\u2019s ultimate sale to AbbVie. Prior to Allergan, Mr. Moore held executive roles at DOV Pharmaceutical and he started his career in the healthcare investment banking group at CIBC Oppenheimer. Mr. Moore earned his B.A. in Psychology from Trinity College.<\/p>\n<p>\n        <strong>About Arcutis &#8211; <\/strong>Bioscience, applied to the skin.<br \/>Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis\u2019 robust <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_2FbmKJgpxTSmkW7MWf1rcvnNC63BXTCUqA6z-AoMLYUtUPb_Rhg_twqm0zDatn2GfZ5z7Uw3C6OVWZ_95bT5A==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">pipeline<\/a> includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The company\u2019s lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GTSUuPtqeUpvPGtyg56bgNHLOtzHU4NTOTy6xyy79tfBcn1YBO1CQ5FoJqYVfmM1lUX-c7BOiter1WraHzFbmxV7DsYebC0VnhzgxpHB0LU=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/www.arcutis.com<\/a> or follow the company on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bQlgkenWZaZtmcDbrCWiVMKahyuShwcMQFgltQNeoxHJtL9172qafFM_ioU3oTmmfU8HMnZVjzB3y5Ik-Lti63JTrIhAYkIvqtZ--Q-hJyI=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Fy6OHRVMBf3caUndvu0cjTb99kU-KD38Su3d-pqEzr-Id2KEnBjQ0jjsestJ1g0MNuDAI8isNOpzhT1WpiB-lg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Twitter<\/a>.<\/p>\n<p>\n        <strong>Forward Looking Statements<\/strong><br \/>\n        <br \/>This press release contains &#8220;forward-looking&#8221; statements, including, among others, statements regarding the potential for Arcutis to become the preeminent, innovation-driven medical dermatology company. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the &#8220;Risk Factors&#8221; section of our Form 10-Q filed with U.S. Securities and Exchange Commission (SEC) on November 5, 2020, as well as any subsequent filings with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.<\/p>\n<p>\n        <strong>Investors and Media:<\/strong><br \/>\n        <br \/>Heather Rowe Armstrong<br \/>Vice President, Investor Relations &amp; Corporate Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0SlkIpmh1E0FmO-d-phJjz1NRPJ5gX13x7m9X_BnAeJJU4kS9YbV0b7PlLWUQUVPS4VD0ACOGvpanww52xfMV8RByTvGFNHZSbj39WFPvHk=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">harmstrong@arcutis.com<\/a><br \/>805-418-5006, Ext. 740<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzM1MiMzOTEyMTczIzIxOTQwNTA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/0a49b13d-699f-4c16-88ed-c963378ba976\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WESTLAKE VILLAGE, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) &#8212; Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Matthew Moore has joined the company as Chief Business Officer. Mr. Moore brings to Arcutis over 20 years of strategy, transaction and operations experience in the biopharmaceutical industry. Most recently, he served as Vice President, Corporate Business Development and Alliance Management at Allergan, where he led worldwide strategy and business development for the company\u2019s $4B+ Medical Aesthetics business unit. \u201cWe are thrilled to add Matt to our executive team. Like the rest of our senior team, Matt brings a deep understanding of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/matthew-moore-joins-arcutis-as-chief-business-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Matthew Moore Joins Arcutis as Chief Business Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-412093","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Matthew Moore Joins Arcutis as Chief Business Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/matthew-moore-joins-arcutis-as-chief-business-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Matthew Moore Joins Arcutis as Chief Business Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WESTLAKE VILLAGE, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) &#8212; Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Matthew Moore has joined the company as Chief Business Officer. Mr. Moore brings to Arcutis over 20 years of strategy, transaction and operations experience in the biopharmaceutical industry. Most recently, he served as Vice President, Corporate Business Development and Alliance Management at Allergan, where he led worldwide strategy and business development for the company\u2019s $4B+ Medical Aesthetics business unit. \u201cWe are thrilled to add Matt to our executive team. Like the rest of our senior team, Matt brings a deep understanding of &hellip; Continue reading &quot;Matthew Moore Joins Arcutis as Chief Business Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/matthew-moore-joins-arcutis-as-chief-business-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-11T14:03:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzM1MiMzOTEyMTczIzIxOTQwNTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matthew-moore-joins-arcutis-as-chief-business-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matthew-moore-joins-arcutis-as-chief-business-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Matthew Moore Joins Arcutis as Chief Business Officer\",\"datePublished\":\"2021-01-11T14:03:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matthew-moore-joins-arcutis-as-chief-business-officer\\\/\"},\"wordCount\":700,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matthew-moore-joins-arcutis-as-chief-business-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzM1MiMzOTEyMTczIzIxOTQwNTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matthew-moore-joins-arcutis-as-chief-business-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matthew-moore-joins-arcutis-as-chief-business-officer\\\/\",\"name\":\"Matthew Moore Joins Arcutis as Chief Business Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matthew-moore-joins-arcutis-as-chief-business-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matthew-moore-joins-arcutis-as-chief-business-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzM1MiMzOTEyMTczIzIxOTQwNTA=\",\"datePublished\":\"2021-01-11T14:03:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matthew-moore-joins-arcutis-as-chief-business-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matthew-moore-joins-arcutis-as-chief-business-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matthew-moore-joins-arcutis-as-chief-business-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzM1MiMzOTEyMTczIzIxOTQwNTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzM1MiMzOTEyMTczIzIxOTQwNTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matthew-moore-joins-arcutis-as-chief-business-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Matthew Moore Joins Arcutis as Chief Business Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Matthew Moore Joins Arcutis as Chief Business Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/matthew-moore-joins-arcutis-as-chief-business-officer\/","og_locale":"en_US","og_type":"article","og_title":"Matthew Moore Joins Arcutis as Chief Business Officer - Market Newsdesk","og_description":"WESTLAKE VILLAGE, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) &#8212; Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Matthew Moore has joined the company as Chief Business Officer. Mr. Moore brings to Arcutis over 20 years of strategy, transaction and operations experience in the biopharmaceutical industry. Most recently, he served as Vice President, Corporate Business Development and Alliance Management at Allergan, where he led worldwide strategy and business development for the company\u2019s $4B+ Medical Aesthetics business unit. \u201cWe are thrilled to add Matt to our executive team. Like the rest of our senior team, Matt brings a deep understanding of &hellip; Continue reading \"Matthew Moore Joins Arcutis as Chief Business Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/matthew-moore-joins-arcutis-as-chief-business-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-11T14:03:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzM1MiMzOTEyMTczIzIxOTQwNTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matthew-moore-joins-arcutis-as-chief-business-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matthew-moore-joins-arcutis-as-chief-business-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Matthew Moore Joins Arcutis as Chief Business Officer","datePublished":"2021-01-11T14:03:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matthew-moore-joins-arcutis-as-chief-business-officer\/"},"wordCount":700,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matthew-moore-joins-arcutis-as-chief-business-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzM1MiMzOTEyMTczIzIxOTQwNTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matthew-moore-joins-arcutis-as-chief-business-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/matthew-moore-joins-arcutis-as-chief-business-officer\/","name":"Matthew Moore Joins Arcutis as Chief Business Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matthew-moore-joins-arcutis-as-chief-business-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matthew-moore-joins-arcutis-as-chief-business-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzM1MiMzOTEyMTczIzIxOTQwNTA=","datePublished":"2021-01-11T14:03:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matthew-moore-joins-arcutis-as-chief-business-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/matthew-moore-joins-arcutis-as-chief-business-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matthew-moore-joins-arcutis-as-chief-business-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzM1MiMzOTEyMTczIzIxOTQwNTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzM1MiMzOTEyMTczIzIxOTQwNTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matthew-moore-joins-arcutis-as-chief-business-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Matthew Moore Joins Arcutis as Chief Business Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/412093","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=412093"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/412093\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=412093"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=412093"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=412093"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}